Background: Rodent approach-avoidance conflict (AAC) tests are common pre-clinical models of human anxiety disorder. Their translational validity mainly rests on the observation that anxiolytic drugs reduce rodent anxiety-like behavior. Here, we capitalize on a recently developed AAC computer game, to investigate the impact of benzodiazepines and of amygdala lesions on putative human anxiety-like behavior. In successive epochs of this game, participants collect monetary tokens on a spatial grid while under threat of virtual predation.
Introduction
Preclinical rodent models of anxiety disorders commonly involve a conflict between approach and avoidance motivation (1) (2) (3) . This conflict can arise from the drive to explore versus the adversity of unprotected exploration as exemplified in the elevated plus maze (4; 5) , open field test (6) , or lightdark box (7) . In other often-used paradigms, a tendency to approach rewards (e.g., food or water) conflicts with avoidance of negative consequences as in Geller-Seifter and Vogel operant conflict tests involving electric shocks (8; 9) , or in novelty-suppressed feeding tests (10) . In all of these approach-avoidance conflict (AAC) paradigms, acute administration of benzodiazepines and other anxiolytics reliably reduces adaptation to threat, i.e., animals behave less cautiously (1) (2) (3) . The same substances also relieve clinical manifestations of anxiety in humans (1-3); see (11; 12 ) for reviews of pharmacotherapy in clinical anxiety. This pharmacological evidence constitutes the main argument for the translational validity of AAC paradigms as models of human anxiety disorders. Still, the crossspecies validity of AAC is not firmly established since suitable pre-clinical test beds for humans have only recently been developed in the form of computer games (13) (14) (15) (16) (17) (18) . The neural implementation of human anxiety-like behavior thus remains elusive.
A plethora of studies have addressed the neurobiological implementation of rodent anxietylike behaviors. They have consistently shown that hippocampus theta oscillations are increased during AAC (19) , and that ventral hippocampus lesions have effects similar to anxiolytics (20) (21) (22) . However, rodent amygdala lesions did not affect innate anxiety-like behaviors, and rendered behavior in AAC with overt rewards more, rather than less, cautious (23) . This is in contradistinction to a role of the amygdala not only in eliciting acute fear responses but also in modulating anxiety-like behavior to context (24) (25) (26) .
Interestingly, the amygdala is rich in the molecular targets of benzodiazepines (27) , namely GABA A receptors (28; 29) . In rodents, local administration of benzodiazepines into the amygdala has anxiolytic effects in operant conflict tests and the light-dark box (27) . In humans, the amygdala is critically required for storing threat memories (30) , and benzodiazepine administration reduced amygdala activity in one human neuroimaging study (31) ; see (32) . Thus, it appears plausible that benzodiazepines may reduce anxiety-related behavior by inhibiting amygdala neurons, in addition to potential effects in the hippocampus. While some functional neuroimaging studies on human AAC have reported involvement of the hippocampus (15; 16) , others report activity of the amygdala (13; 14) . Results from a lesion study suggest causal involvement of the human hippocampus in AAC behavior (15) .
Here, we sought to investigate the impact of benzodiazepines and of amygdala lesions on human AAC. In our behavioral task (15) (Figure 1 ) participants forage for monetary tokens in successive epochs under threat of a virtual predator that can take away these tokens. Thus, this task explicitly pits rewards (monetary tokens) against punishment (capture by predator and thus loss of previously collected tokens).
Normatively, an agent should adapt behavior over time within an epoch (cf. (17) ). As the number of collected tokens increases over time, potential loss increases, and participants should become more cautious by staying close to the safe place. Based on our previous report (15) , we defined linear intra-epoch adaptation of presence in the safe quadrant (i.e., the quarter of the field surrounding the safe place) as primary outcome measure. In other words, we hypothesized a linear drug × time and lesion × time interaction in this measure, with a smaller effect of time under lorazepam and in lesion patients. As secondary outcomes, we investigate six further behavioral metrics (15) . In our previous investigation (15) , these metrics were inter-correlated-similar to measures from rodent AAC (33; 34). Therefore, we additionally introduce a summary score that quantifies loss adaptation over intra-epoch time as a weighted average of the rate of change per time unit across all seven metrics.
We first inquire whether human anxiety-like behavior in AAC is reduced by lorazepam, as it is in rodents. Next, we seek to quantify to what extent the amygdala contributes to anxiety-like behavior, by comparing two patients with relatively specific lesions of the bilateral amygdala due to congenital Urbach-Wiethe syndrome (35) (36) (37) (38) with age-and gender-matched healthy individuals, and contrasting these results to a previously reported sample of patients with hippocampal lesions due to sclerosis (15) .
Methods

Lorazepam study: Participants, study medication, ethics, and registration
Participants were recruited from the general population (overall n=60; 30 per group; 15 female per group; one female participant was excluded from analysis due to a suspected medical condition). Age of the resulting sample was (mean ± SD) 25.1 ± 4.4 years and did not differ between groups (p>.1).
The study medication was 1 mg oral lorazepam (Temesta®, Pfizer). Peak plasma concentrations are reached after approximately 120 min (39; 40) . See also Supplementary Methods.
The study was conducted in accord with the Declaration of Helsinki and approved by the governmental research ethics committee (Kantonale Ethikkomission Zurich, KEK-ZH-Nr. 2014-0196) and the Swiss Agency for Therapeutic Products (Swissmedic, 2014DR1113). All participants gave written informed consent. The study was pre-registered at the Swiss Federal Complementary Database (KOFAM; SNCTP000001227) and at the WHO International Clinical Trials Registry Platform (ICTRP; ISRCTN12590498; http://www.isrctn.com/ISRCTN12590498).
Amygdala study
Two female monozygotic twins (age 40 years) with selective bilateral amygdala lesions due to Urbach-Wiethe syndrome were tested at University of Bonn. Seventeen healthy female participants 
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Neurological and psychological examinations of the two lesion patients have been extensively reported (35-37; 41) . High-resolution computer-assisted tomography images showed that the calcified volumes include the entire basolateral amygdala and most other amygdala nuclei (see Figures 1 and S3 in (35) ). The hippocampus itself is free of calcifications. There are mild calcifications at the border region between amygdala and hippocampus (35) .
The two patients did not meet criteria for any psychiatric disorder and were not taking any psychotropic medication at the time of testing. One of the twins suffered a first grand-mal seizure at age 12 but stopped anticonvulsive therapy with a then 900-mg daily dose of valproate in 2006, when she became pregnant (35) ; the other patient never had seizures. Both patients report pre-epileptic auras that occur up to twice a month.
An extensive neuropsychological test battery conducted at the age of 34, reported in (41), showed no signs of anxiety or depression (HDRS-21, HARS, BDI-II) and no psychopathological symptoms (SCL-90-R). Both twins had average intelligence, as well as intact verbal learning and memory (as assessed among others by the VLMT, Verbaler Lern-und Merkfähigkeitstest, a German version of the RAVLT, Rey Auditory Verbal Learning Test; see (41; 42) 
Behavioral approach-avoidance paradigm
Participants completed 240 epochs of our previously described AAC task on a standard PC (15) , divided into five blocks with short self-paced breaks. In each epoch, participants could move over grid of a 24 × 16 blocks in order to collect monetary tokens under the threat of being attacked by a predator, which resulted in the loss of all tokens collected in the given epoch. One corner of the grid was a safe place, in which the predator could not attack. We refer to the quarter of the grid in which the safe place was located as -safe quadrant‖ (constituting of 12 × 8 grid blocks). Location of the safe place was randomized on each epoch.
Tokens:
At all times, ten tokens were present on the grid, uniformly distributed in space, and every 2 s one of the tokens changed its position randomly. When participants collected a token, it was added to a row in the upper left corner of the computer screen (above the grid), and a new token appeared in a different place on the grid.
Predator: In the beginning of each epoch, a predator was inactive in a corner of the grid (diagonal to the safe place). The -threat quadrant‖ constituted the quarter of the grid in which the inactive predator resided (12 × 8 blocks) and was always diagonal to the safe quadrant. The predator could become active and chase participants any time, but could not enter the safe place. Color of the frame around the grid (blue, purple, orange) indicated three distinct predator wake-up probabilities (0.2, 0.5, and 0.8). These threat probabilities were not explicitly revealed beforehand; participants learned to distinguish the different threat levels during the game. Threat levels were balanced across epochs.
Active versus passive start: Participants started each epoch either in the same corner as the predator (active start) or from the safe place (passive start). Starting corner was balanced across epochs. See also Supplementary Methods.
Statistical analyses of the behavioral paradigm
We analyzed participants' positions on the grid over 1 s bins. Since epoch duration was variable, more data was available for earlier than for later time bins. Presence in safe quadrant during foraging phase constituted our primary outcome measure. We also analyzed the following six secondary outcome measures: (1) distance from threat (i.e., from the predator), (2) distance from nearest wall, (3) presence in safe place, (4) presence in threat quadrant, (5) token collection, and (6) speed when outside safe place. Our factorial design included a between-subjects factor (Lorazepam/Placebo; or Amygdala lesions/healthy controls) and three within-subjects factors: task (active/passive start), threat level of predator (low/medium/high), and time (15 time bins of 1 s 8 duration)]. Secondary outcome measures were Bonferroni-corrected to account for multiple comparisons. For ease of presentation, and to facilitate comparison of significance across primary, secondary and additional measures, we state p-values multiplied by the number of measures in the correction, rather than adapting significance thresholds. Resulting values exceeding 1 are stated as 1.
We used the software package R to perform full multistratum repeated-measures ANOVA model with Greenhouse-Geisser corrected degrees of freedom, and Bonferroni correction for six measures per experiment for the secondary outcomes. Patients with selective amygdala lesions are extremely rare and often studies have to rely on single cases (35; 43; 44) . Our experimental design necessitates a parametric three-factorial analyses, for which no single-case statistics are available unlike for simpler experimental designs (45) . Crucially, using multi-level repeated-measures ANOVA models considerably mitigates the concern of limited sample size because all individual responses enter the design matrix under the assumption of equal variance across all cells of the design.
For each of the seven measures we computed subject-by-subject regression models for the linear effect of time (i.e., 15 time bins). We weighted the individual measures according to their respective theoretical maximum range and summed them to a loss adaptation score. To validate this score, we show that it was significantly reduced in patients with hippocampus sclerosis (n=7) compared to healthy controls from our previous data set (15) (n=12; t(17)=2.8; p=.0135 two-tailed; Figure 4 ). In the present data sets (lorazepam and amygdala studies), we report one-tailed tests as we had a directional hypothesis.
Results
Lorazepam reduces anxiety-like behavior in a randomized, double-blind, placebo controlled study
Lorazepam had a significant impact on our primary outcome. To address whether the less cautious strategy induced by lorazepam is maladaptive in our ACC task, we compared the average number of tokens retained at the end of each epoch, including the chase phase. No significant overall group difference emerged (p>.1; Table S1 ). This implies that both groups maximize token collection in the game, but by using different strategies. Specifically, participants under lorazepam were more daring and successful during token collection but were thus caught more often, which resulted in an overall number of tokens retained similar to participants under placebo.
There was no group difference in explicit ratings of predator probability or preference for the three predators (all p's>.1; Table S1 ) and including these measures as covariates (together with their time interaction) led to the same pattern of results for the individual metrics (Table S2 ) and the loss adaptation score (Table S1 ). Within the placebo group, participants' behavior was influenced by threat level and generally similar to the behavior of healthy participants in our previous report (15) (Figures S1 & S2; Table S3 ).
Sedation does not explain the effects of lorazepam on anxiety-like behavior
Saccadic peak velocity, a sensitive measure of benzodiazepine-induced drowsiness (40; 46-50), did not differ between groups immediately before and after the game (p>.1; see Supplementary Methods and Table S4 ). Including saccadic peak velocity (measured pre-or post-task) as a covariate (together with its time interaction) did not change the results of the group comparison for any of our outcome measures (Tables S2 & S4) . Furthermore, reaction times in the game, i.e., foraging latencies and escape latencies (when the predator woke up), did not differ between the groups (p>.1; Table S1 ).
Two patients with congenital amygdala lesions show reduced anxiety-like behavior relative to healthy controls
Patients with amygdala lesions, compared to the control group, spent less time in the safe quadrant as intra-epoch time progressed (t=-4.5; p=0.0112; Table 1; Figure 2) . A similar pattern was found in three of the six secondary measures after Bonferroni correction (Table 1; Figure 3 ):
Compared to control participants, lesion patients were less often in the safe place (t=-6.2; p=.0276), collected more tokens (t=4.3; p=.0354), and had higher speed when outside the safe place (t=3.7;
p=.0276), as the epoch progressed. Trends emerged in two measures: Patients kept relatively less distance from threat (t=-5.2; p=.0510) and relatively more distance from the nearest wall (t=4.1; p=.0792). Again, this was reflected in a smaller loss adaptation score (t(17)=1.7; p=.0539; Figure 4) .
The overall number of tokens retained at the end of all epochs did not differ between groups (p>.1; Table S5 ). There was no evidence for general motor slowing in the lesion group since escape latencies were comparable between groups (p>.1; Table S5 ).
The two groups showed trend-wise group × threat interactions in two measures of explicit threat knowledge, such that the amygdala lesions patients estimated the wake-up of predator with the highest threat level as particular probable (t=1.8; p=.0763) and early (t=-1.8; p=.0892; Table S5 ).
However, no overall group difference emerged (all p's<.1), and a covariance analysis revealed that the difference in loss adaptation score was in a similar range when accounting for these subjective reports (Table S5 ). Overall behavior of the control group was comparable with our previous results in healthy participants (15) (Figures S1 & S2; Table S6 ).
Amygdala and hippocampus lesions had comparable behavioral effects
Finally, we quantitatively compared the effect due to lesions to the amygdala, as demonstrated in the current report, and hippocampal lesions, as shown in our previous report (15) . Of note, lesions were selective to the amygdala or the hippocampus (for detailed descriptions see Methods). The calcifications in the two Urbach-Wiethe patients did not extend to the hippocampus itself and the patients previously scored normal on memory tests (including a German version of the RAVLT, Rey Auditory Verbal Learning Test). Conversely, amygdala tissue was spared in the hippocampus lesion patients.
We used a 2 (lesion/control) × 2 (study group: amygdala/hippocampus) ANOVA (see also Figure 4 ). In this analysis, dissociation between the effect of hippocampus and amygdala lesions would be revealed as lesion × study group × time interaction, and an overall impact of lesion as lesion × time interaction. We found a lesion × time interaction for the primary measure, presence in the safe quadrant (t=-9.6; p<.0001); and for five out of six secondary measures (distance from threat: t=-10.0; p<.0001; distance from nearest wall: t=-9.0; p<.0001; presence in safe place: t=-6.5; p<.0001; presence in threat quadrant: t=5.0; p<.0001; token collection: t=8.5; p<.0001; Figures 2 & 3) . A significant lesion × study group × time interaction was found for one of the metrics (presence in safe place; t=-3.7; p=.0020). However, post hoc comparisons showed that in this measure, the two control groups differed more than the lesion groups, and the descriptive pattern suggests that floor effects contributed to this interaction (Figure 3 , see also Figure S2 ). Relatedly, a main effect of lesion emerged on the loss adaptation score (F(1,34)=8.1; p=.0074), but no significant lesion × study group interaction and no main effect of study group (both p's>.1).
Discussion
Anxiolytics influence both rodent AAC behavior and human clinical anxiety, and this is often taken to suggest that AAC is a valid pre-clinical anxiety model (51) . Here, we demonstrate that the benzodiazepine lorazepam reduces anxiety-like behavior in human AAC. We then investigate two patients with selective bilateral amygdala lesions due to congenital Urbach-Wiethe disease, and show that these patients exhibit reduced anxiety-like behavior. Interestingly, behavior of these two amygdala patients does not differ from a previously investigated group of individuals with hippocampal sclerosis.
Detailed control analyses make it unlikely that drug side effects are responsible for the impact of lorazepam. Reaction times, both in the beginning of an epoch and when the virtual predator became active, did not differ between groups. Furthermore, we did not observe group differences in saccadic eye movements, a sensitive marker of benzodiazepine-induced sedation, both immediately before and after the AAC test. Overall, our results suggest that behavioral effects of benzodiazepines in human AAC are homologous to those in classic rodent AAC. This provides a neuropharmacological validation of our virtual AAC paradigm and thus distinguishes it from more common human anxiety tests such as public speaking anticipation which is not sensitive to anxiolytic drugs and instead responds to acute administration of serotonergic substances (52) .
Benzodiazepines bind allosterically to GABA A receptors and thereby increase the inhibitory action of GABA (28) . Among other regions, GABA A receptors are prominently expressed in the amygdala in both rodents (27; 53) and humans (54) , which points to a possible role of the amygdala in anxiety-related behaviors. Additionally, electrophysiological recordings in rodents during an AAC have recently indicated a role of the amygdala (26) ; in addition to previous demonstrations of hippocampal involvement (55) . Functional neuroimaging studies in humans suggest that the amygdala may mediate the anxiolytic effect of lorazepam in an emotional face assessment task (31) . By demonstrating a critical role of amygdala lesions on human AAC, our findings offer a missing link between assessments of human and rodent anxiety. Strikingly, we observed similar effects as in the lorazepam group: As intra-epoch-time passed, lesion patients spent less time in the safe place, collected more tokens, and were faster outside the safe place, compared to a control group.
These findings in the amygdala lesion group qualitatively and indeed quantitatively mirror the reduction in loss adaptation that we have previously reported for a group with hippocampal lesions (15) (see Figures 2 & 3) . This raises the pertinent question whether amygdala and hippocampus lesions affect the same or complementary components. Potentially, the two structures could mediate approach versus avoidance behaviors in a differential manner that is not immediately obvious in our task. Our measures of anxiety-like behavior can result from decreased approach and/or increased avoidance, and may possibly relate to influences of the hippocampus and the amygdala respectively.
Paradigms with better segregation of individual actions are required to answer this question (17) .
Our results relate to two recent studies in non-human primates making cost-benefit decisions between unpleasant stimuli and liquid rewards (56; 57) . In one of these two studies, benzodiazepine 13 administration increased approach decisions during AAC (56) . In addition, benzodiazepine partly reversed the effects of electric stimulation to the pregenual cingulate cortex, which shifted the baseline approach-avoidance balance toward avoidance (56) . In another monkey study, disrupting the amygdala-hippocampus circuit abolished an approach-avoidance imbalance that was induced by inactivating the anterior orbitofrontal cortex (57) . In human anxiety-like behavior, the interplay of cingulate and orbitofrontal cortex with amygdala-hippocampus circuits remains to be investigated.
The bed nucleus of the stria terminalis (BNST) represents an additional candidate region that can be expected to influence anxiety-like behavior since it is interconnected with the amygdala as Although there is no evidence of BNST lesions in our sample, the amygdala provides important BNST inputs which are likely to be damaged in our lesion patients.
Hippocampal sclerosis and Urbach-Wiethe disease, the two lesion models investigated in this and our previous report (15) , gradually encroach during brain development. It is possible that other brain structures can over time compensate for some loss of function due to such deteriorating hippocampus or amygdala deficiencies. These lesion models are thus not directly comparable to acute brain lesions in non-human animals and we cannot disentangle whether acute or developmental effects underlie the observed impact of lesions on anxiety behavior. Testing patients with acute lesions could mitigate such concerns. Additionally, we cannot dissect the precise subregions of the amygdala or the hippocampus responsible for the observed effects, and we cannot entirely rule out an impact of damage to traversing or nearby fibers tracts.
Interestingly, some drugs that affect the GABAergic system such as valproic acid appear anxiolytic in rodent AAC but have not been validated in clinical conditions (65-67). The reason for this discrepancy is as yet unclear. With our AAC paradigm, we furnish a platform for pre-clinical drug testing in humans and thus elucidating possible species differences in anxiolytic drug action.
In conclusion, we investigate the impact of benzodiazepines and amygdala lesions on behavior in a human analogue of animal AAC paradigms, which are extensively used in the preclinical evaluation of anxiolytics (1) (2) (3) . We demonstrate that loss adaptation in our paradigm, a critical measure of anxiety-like behavior, is reduced both by benzodiazepines and by amygdala lesions. Furthermore, there is no qualitative and indeed no appreciable quantitative difference between an effect of amygdala and hippocampal lesions on anxiety-like behavior. This provides a crucial link between investigations on animal models of anxiety, which has often focused on the rodent hippocampus (20; 21), and research on human anxiety, which tends to stress the role of the amygdala (30; 68-71) . In a wider context, our approach of using behavioral measures in well-defined paradigm is in line with a recent proposal that emphasizes the need to dissociate behavioral symptoms and subjective experience of anxiety in basic research (72; 73) and in clinical conditions (74) . By suggesting a missing link between human and animal work on anxiety, we hope to have advanced the understanding of the neural mechanisms supporting anxiety-like behavior. The proportion of time spent in the safe quadrant (see Figure 1 ) shows group differences for lorazepam-versus placebo-treated healthy participants, as well as for amygdala and hippocampus lesion patients versus respectively matched controls (see Table 1 for statistical results, Figure 3 for results on the six secondary outcome measures and Figure 4 for results on the loss adaptation score that combines the seven measures). As intra-epoch time progresses, the control groups spent more time in the safe quadrant than the drug or lesion groups (in both active and passive epochs; i.e., the black lines are above the dark red lines for all three experiments). The inset in the left column depicts group differences. As per task design, the initial phase of the epoch is characterized by substantial 23 differences between active epochs (in which the player and the predator start in the same corner) and passive epochs (in which the participant starts in the safe place).
Figures and Figure Legends
Figure 3. Six secondary metrics of loss adaptation in the approach-avoidance paradigm.
Individual metrics show group differences for lorazepam-versus placebo-treated healthy participants, as well as for amygdala and hippocampus lesion patients versus respectively matched controls (see Table 1 for statistical results, Figure 2 for results on the primary outcome measures and Figure 4 for results on the loss adaptation score that combines the seven measures). Mean data are plotted for time points in which data from all participants are available (e.g., speed outside the safe place is not shown for some later time points since many participants tend to reside in the safe place toward the end of the epoch).
Figure 4. Loss adaptation scores in the approach-avoidance paradigm
Loss adaptation in the game is reduced under lorazepam versus placebo and in two patients with amygdala lesions versus healthy controls. This mirrors reductions of loss adaptation in patients with hippocampus lesions; reanalyzed from (15) . The loss adaptation score combines the seven behavioral metrics of the AAC paradigm (see Figures 2, 3, S1, & S2) . The overall differences in loss adaptation 24 scores between the three groups are likely due to age differences (mean ± SD of the three samples in years: Lorazepam study: 25.1 ± 4.4; Amygdala lesions study: 40.2 ± 3.0; Hippocampus lesions study:
44.0 ± 9.3). As a side finding, we observed that loss adaptation score correlated negatively with age across the three control groups (Pearson's r=-0.41; p=.0013). Error bars depict standard errors of the mean. on both studies see Figure S1 . For more results of the lorazepam study see also Tables S1-S4. For more results of the amygdala study see also Figure S3 and Tables S5 & S6. 
